| 钾离子竞争性酸阻滞剂的药学特征研究进展 |
| 投稿时间：2023-06-27 修订日期：2024-03-14 点此下载全文 |
| 引用本文：王耀振,徐灿,吕顺莉,田泾,张东炜.钾离子竞争性酸阻滞剂的药学特征研究进展[J].药学实践杂志,2024,42(7):278~284 |
| 摘要点击次数: 51 |
| 全文下载次数: 50 |
|
|
| 中文摘要:钾离子竞争性酸阻滞剂（P-CAB）是一类新型抑酸药，通过与H+, K+-ATP酶的K+结合位点附近可逆结合，抑制其构象转变而无法完成H+、K+交换，以K+竞争性的方式抑制胃酸分泌。P-CAB独特的结构与新颖的作用机制赋予其优于其他质子泵抑制剂（PPI）的药学特征，使其成为了酸相关性疾病（ARDs）的新选择。就P-CAB的药学特征展开综述。 |
| 中文关键词:钾离子竞争性酸阻滞剂|酸相关性疾病|研究进展 |
| |
| Progress on pharmaceutical characteristics of potassium-competitive acid blocker |
|
|
| Abstract:As a new class of acid inhibitors, potassium-competitive acid blocker（P-CAB） inhibits the conformational transition of H+, K+-ATPase with subsequent suppression of H+, K+ exchanging by binding reversibly near the K+ binding site of H+, K+-ATPase, which results in the inhibition of gastric acid secretion in a K+-competitive manner. The unique structure and novel mechanism of P-CAB contribute to the pharmaceutical characteristics superior to other PPIs, making it a new alternative for acid-related diseases（ARDs）. Progress on pharmaceutical characteristics of P-CAB were reviewed in this paper. |
| keywords:potassium-competitive acid blocker|acid-related diseases|progress |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
